New peripherally-restricted CB1 receptor antagonists, PMG-505-010 and -013 ameliorate obesity-associated NAFLD and fibrosis.

MLA

Yang, Hyekyung, et al. “New Peripherally-Restricted CB1 Receptor Antagonists, PMG-505-010 and -013 Ameliorate Obesity-Associated NAFLD and Fibrosis.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, vol. 180, Nov. 2024, p. 117501. EBSCOhost, https://doi.org/10.1016/j.biopha.2024.117501.

APA

Yang, H., Park, M., Lee, J. H., Kim, B., Moon, C. S., Bae, S., Kim, Y., Lee, H.-J., & Park, C.-Y. (2024). New peripherally-restricted CB1 receptor antagonists, PMG-505-010 and -013 ameliorate obesity-associated NAFLD and fibrosis. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie, 180, 117501. https://doi.org/10.1016/j.biopha.2024.117501

Chicago

Yang, Hyekyung, Miey Park, Ji Hye Lee, Bokyoung Kim, Chang Sang Moon, Suyeal Bae, Younghoon Kim, Hae-Jeung Lee, and Cheol-Young Park. 2024. “New Peripherally-Restricted CB1 Receptor Antagonists, PMG-505-010 and -013 Ameliorate Obesity-Associated NAFLD and Fibrosis.” Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie 180 (November): 117501. doi:10.1016/j.biopha.2024.117501.